Guide
Ketamine Therapy for Depression: Understand the Treatment First
Ketamine therapy for depression can mean an off-label clinic treatment or a compounded at-home program; these are not the same as FDA-approved Spravato esketamine. The evidence, supervision, product and cost differ. Before booking, ask a clinician what treatment is appropriate for your diagnosis and what evidence applies to that exact route and setting.
The practical goal is a care plan with clear screening, monitoring, measures of benefit and a next step if it does not help. An impressive claim about “ketamine” alone does not supply those details.
Start by identifying which treatment is being offered
| Option | What to establish before booking |
|---|---|
| Spravato esketamine nasal spray | Whether your diagnosis fits an approved indication; certified setting, monitoring and coverage |
| Clinic-based ketamine | The product, route, off-label use, clinician oversight and full treatment price |
| Compounded at-home ketamine | The prescription product, pharmacy, home safety requirements and support actually included |
| Ketamine-assisted psychotherapy | Whether licensed psychotherapy is included or charged separately; who provides it and how it is coordinated |
The FDA's compounding information explains why compounded products do not have FDA approval. The current Spravato guide describes its approved adult depression uses and required setting. See Spravato vs ketamine for the detailed distinction.
What the evidence can and cannot tell you
Research evidence is tied to the treatment studied. A trial of intravenous ketamine in a supervised setting does not establish the effectiveness of every oral home program. A provider's before-and-after survey is not the same design as a randomized controlled trial.
When evaluating an outcome claim, look for these details:
- The diagnosis and prior treatments of the participants.
- The medicine, administration route, support and setting.
- The number of people who started and who supplied follow-up data.
- The comparison group, if any.
- The definition of improvement or remission and when it was measured.
- What happened after the initial treatment period.
Ask the clinician to explain how the evidence applies to your history. This page does not convert study results into a prediction for you, or use a provider's marketing percentage as a ranking.
What a major ketamine trial found
A 2023 randomized, open-label trial compared supervised intravenous ketamine with ECT in adults referred for treatment-resistant depression without psychosis. In the treated population, 108 of 195 ketamine participants (55.4%) and 70 of 170 ECT participants (41.2%) met the trial's response definition after the initial three-week treatment phase. Response meant at least a 50% reduction on a specified depression symptom scale; it did not mean a permanent cure.
The trial met its prespecified noninferiority test. It was not blinded, studied a selected population, and does not establish results for psychotic depression, every clinical situation or an oral at-home program. Source: Anand and colleagues, New England Journal of Medicine, 2023.
How quickly does treatment work, and will benefit last?
Some controlled studies have detected symptom improvement within hours or a day, but the timing depends on the treatment studied. Those results do not establish when you will feel better or how long a benefit will last.
| Treatment and study | What the study actually measured | What you should not assume |
|---|---|---|
| Supervised IV ketamine, small 2006 treatment-resistant-depression trial | Eighteen adults enrolled; 17 received ketamine. Group improvement versus placebo was detectable at the 110-minute assessment. The day after infusion, 71% met the study's response threshold; 35% maintained response for at least a week | That the same timing or percentages apply to an oral home program, or that early relief is permanent |
| Esketamine nasal spray without an oral antidepressant, 2025 TRD trial | In the 378-person efficacy population, both studied esketamine groups had greater average symptom-score improvement than placebo about 24 hours after the first treatment; the primary assessment was day 28 | That an average group difference predicts your response, or applies to a compounded ketamine product |
| Supported at-home sublingual ketamine, 2022 observational study | Outcomes were assessed over a four-week course; 1,247 treatment completers had enough data for the analysis | That an uncontrolled completer study proves a reliable first-day onset or the effect of every home provider |
Sources: Zarate and colleagues, 2006, Janik and colleagues, 2025, and Hull and colleagues, 2022. These studies used different protocols and outcomes; they are not a ranking of treatment speed.
Early symptom change is different from remission, restored daily functioning or lasting benefit after treatment ends. Ask your clinician when progress will be measured, what counts as enough benefit, when continuing care will be reviewed, and what the plan is if symptoms return. Do not change an existing prescription or choose a treatment schedule from these research examples.
What “off-label” means for depression treatment
Off-label use is use outside an approved product's labeling. It does not itself mean the treatment is illegal. It does mean FDA approval for the original product should not be described as approval for that psychiatric use.
Compounded ketamine has an additional issue: the compounded product itself is not FDA-approved. FDA has described risks associated with psychiatric use and with home administration lacking onsite healthcare monitoring. Read the historical FDA ketamine warning and its current risk-alert listing.
Spravato has specific approved adult depression indications, including treatment-resistant depression with or without an oral antidepressant. Its approval does not make other ketamine products equivalent, nor does it make Spravato right for every person.
What a responsible assessment should clarify
A consultation should review what you have been diagnosed with, what you have tried, other medical conditions, current medicines and whether the proposed setting can meet your needs. A short commercial questionnaire cannot replace that judgment.
Bring a list of past treatments, the reasons each ended and current medicines or supplements. Ask who will coordinate with your regular prescriber or therapist. Do not stop or change medicines on your own to meet program criteria.
Also ask how the provider recognizes worsening symptoms, adverse effects or lack of benefit. You should know who to contact between appointments and what requires urgent care.
Monitoring and support are different services
Ask who will be present during treatment and what they can do. A supportive companion may help with practical needs, while a clinician provides medical assessment and response. Text messaging, an educational app and scheduled coaching are not the same as live clinical monitoring.
For Spravato, the required setting and post-administration monitoring are described in the FDA guide. For another provider, request its actual protocol. Do not assume that a term such as “guided” means a professional is watching throughout the session.
Our safety guide and side-effects guide explain the questions to raise without choosing a dose or screening you into treatment.
Ask what happens after the first sessions
A useful plan explains reassessment rather than simply selling another package. Ask what measure will be used, when you will review it and how the provider considers symptom change, functioning and side effects together.
Clarify whether future treatment is included, separately priced or only discussed later. Also clarify whether psychotherapy or integration support is available, what credentials the person providing it holds and what happens if you need a different level of care.
You do not need a promise of permanent relief. You need a clear plan for following your progress and changing course when necessary.
What does ketamine therapy for depression cost?
The price depends on the route and care model. Compare total quoted program costs, not only a per-session figure, a monthly financing payment or a medication copay.
List the evaluation, medicine, monitoring, support, additional appointments and travel separately. Ask whether ongoing care costs extra. Read ketamine therapy cost for the comparison framework and insurance coverage before assuming a superbill will be reimbursed.
A sensible next step
If you are exploring options, start with your existing clinician and the treatment model that needs clarification. For a supervised approved option, read the Spravato review. For home-program logistics and prices, use the at-home ketamine comparison after discussing whether home care is appropriate.
If you need urgent help for worsening mental health or immediate safety concerns, seek urgent or emergency care. A new treatment inquiry should not delay that help.
How we checked this guide
Checked November 17, 2026 using FDA labeling and compounding information. This guide explains evidence and access questions; it does not diagnose depression, determine eligibility or recommend a treatment plan. No firsthand treatment or medical review is claimed.